{"url_path":"/sec/ptct/8-k/2026-06-18/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-075731-index.html","accession_number":"0001104659-26-075731","cik":"0001070081","ticker":"PTCT","issuer_name":"PTC THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-075731-index.html","primary_entity_key":"0001070081","primary_entity_name":"PTC THERAPEUTICS, INC."},"word_count":78,"has_tables":true,"body_markdown":"**Item 8.01.**\n**Other Events.**\n\n \n\nThe Company is using approximately $328.8 million of the net proceeds from\nthe offering to repurchase for cash $222.0 million in aggregate principal amount of the Existing Convertible Notes pursuant to privately\nnegotiated transactions with certain holders entered into concurrently with the pricing of the offering of the Notes. After\ngiving effect to such expected repurchases of the Existing Convertible Notes, the aggregate principal amount outstanding of Existing Convertible\nNotes would be $55.5 million."}